±èÁÖÇ×
¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, µÎ°æºÎ¾Ï, ½Äµµ¾Ï
Á÷
ˤ
: ±³¼ö(¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
74
ÇØ¿Ü
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer
73
ÇØ¿Ü
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
72
ÇØ¿Ü
Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Non-Small-Cell Lung Cancer
71
±¹³»
The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer
70
ÇØ¿Ü
Complete Response of Recurrent Squamous Cell Carcinoma of the Lung: Dose the Dose Matter?
69
ÇØ¿Ü
Brain metastases from hepatocellular carcinoma: prognostic factors and outcome
68
ÇØ¿Ü
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
67
ÇØ¿Ü
Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer
66
±¹³»
ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀ¸·Î ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á°¡ ½ÃÇàµÈ N2º´±â ȯÀڵ鿡¼ ´Ù¹ß ºÎÀ§ Á¾°Ýµ¿ ¸²ÇÁÀý ÀüÀÌ ¿©ºÎ¿¡ µû¸¥ N2º´±â ±¸ºÐÀÇ ÀÓ»óÀû ÀǹÌ
65
ÇØ¿Ü
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729